Crebanine transdermal patch and preparation method thereof

Abstract

The invention relates to a crebanine transdermal patch and a preparation method thereof. The crebanine transdermal patch is formed by sequentially overlapping a back lining layer, a medicine-containing adhesive layer and a protective layer, wherein the medicine-containing adhesive layer is prepared from the following components in parts by weight: 0.03 to 0.135 part of crebanine or crebanine hydrochloride, 0.03 to 0.09 part of cross-linking agent, 0.3 to 0.9 part of pressure sensitive adhesive, 0.19 to 0.63 part of plasticizer, 0.1 to 0.3 part of moisturizer, and 0.007 to 0.206 part of percutaneous penetration enhancer. The crebanine transdermal patch has relatively good percutaneous absorption, is more lasting in action time than that of an oral preparation, is more convenient to use than an injection preparation, is good in compliance of patients, and has the characteristics of security, effectiveness, convenience in using, and no irritation and toxicity. Crebanine in the transdermal patch disclosed by the invention is relatively high in cumulative infiltration capacity and can maintain effective blood drug concentration for a longer time, has obvious and lasting antiarrhythmic effect, and overcomes the phenomena that the lasting time of arrhythmia caused by intravenous injection or gastric infusion administration is relatively short and relapse easily occurs.

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a carbanin transdermal patch with antiarrhythmic effect and a preparation method thereof. Background technique

[0002] Cardiac arrhythmia is a common clinical disease, mild cases affect the quality of life and work, and sudden cardiac death caused by malignant arrhythmia such as ventricular tachycardia, ventricular fibrillation, atrial fibrillation, etc. is the main cause of death from cardiovascular diseases. The incidence of the disease has been younger and growing trend. Drugs currently used in clinical prevention and treatment of arrhythmia can be divided into four categories: Category I: sodium ion channel blockers, divided into three subcategories IA, IB, and IC. Class Ⅱ is β-adrenoceptor blockers, such as metoprolol. Class III is a potassium channel blocker, a drug that selectively prolongs the repolarization process. They prolong the action potential durat...

Images